Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis

Hepatology

Volumn 17, Issue 1, 1993, Pages 78-83

  Violi, Francesco ^a   Ferro, Domenico ^a   Quintarelli, Claudio ^a   Musca, Antonio ^a   Balsano, Francesco ^a   Cordova, Corrado ^a   Basili, Stefania ^a   Group, The Calc ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL FEATURE; DISEASE CLASSIFICATION; FEMALE; FIBRINOGEN METABOLISM; FIBRINOLYSIS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; BLOOD COAGULATION; FEMALE; FIBRINOLYSIS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGE; PLASMINOGEN INACTIVATORS; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0027471093     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840170115     Document Type: Article

References (36)

1. Hemostatic abnormalities in liver disease
2. Disordered hemostasis in hepatic disease
3. Prekallikrein and factor VII as prognostic indexes of liver failure
4. Bleeding time in patients with hepatic cirrhosis
5. Platelet lipid composition and platelet aggregation in human liver disease
6. Reduced platelet thromboxane A2 production as a possible cause of defective platelet aggregation in cirrhosis
7. Clinical significance of accelerated fibrinolysis in liver disease
8. Plasminogen activators of alcoholic cirrhosis: demonstration of increased tissue type and urokynase type activator
9. Analysis of elevated fibrin(ogen) degradation products levels in patients with liver disease
10. Clotting abnormalities in liver cirrhosis
11. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage
12. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis
13. Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis
14. Evaluation of D‐dimer in patients with liver cirrhosis
15. Transection of oesophagus for bleeding oesophagus varices
16. A peek at the Child‐Turcotte classification
17. Geriunungphisioiogische schnellmethode zur bestimmung des fibrinogens
18. Immunochemical quantitation of antigens by single radial immunodiffusion
19. Interrelation between factor VII, prekallikrein and hyperfibrinolysis in advanced cirrhosis
20. Relationship between elevated plasma levels of crosslinked fibrin degradation products (XL‐FDP) and the clinical presentation of patients with myocardial infarction
21. Disseminated intravascular coagulation in cirrhosis
22. Sandwich ELISA for t‐PA antigen employing a monoclonal antibody
23. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay
24. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibodybased enzyme‐linked immunosorbent assay
25. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
26. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis
27. Hyperfibrinolysis increases the risk of gastrointestinal haemorrhage in patients with advanced liver cirrhosis
28. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for plasminogen activator inhibitor
29. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis
30. Abnormal plasminogen plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences
31. Uptake and degradation of tissue plasminogen activator in rats liver
32. Diagnosis of DIC: role of D–dimer
33. Thrombin and plasmin generation in patients with liver disease
34. Fibrinolysis and fibrinogenolysis in liver disease
35. Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure